Miralax and Clindamycin phosphate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Miralax and Clindamycin phosphate. Common interactions include chest pain among females and atrial fibrillation among males.

The phase IV clinical study analyzes what interactions people who take Miralax and Clindamycin phosphate have. It is created by eHealthMe based on reports of 60 people who take Miralax and Clindamycin phosphate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

60 people who take Miralax and Clindamycin phosphate together, and have interactions are studied.


What is Miralax?

Miralax has active ingredients of polyethylene glycol 3350. It is often used in constipation. eHealthMe is studying from 72,729 Miralax users for its effectiveness, alternative drugs and more.

What is Clindamycin phosphate?

Clindamycin phosphate has active ingredients of clindamycin phosphate. It is often used in infection. eHealthMe is studying from 3,458 Clindamycin phosphate users for its effectiveness, alternative drugs and more.

Number of Miralax and Clindamycin phosphate reports submitted per year:

Miralax and Clindamycin phosphate drug interactions.

Common Miralax and Clindamycin Phosphate drug interactions by gender *:

female:

  1. Chest pain
  2. Death
  3. Decreased appetite
  4. Dehydration
  5. Depression
  6. Disease progression
  7. Disturbance in attention
  8. Drug ineffective
  9. Epistaxis
  10. Facial bones fracture

male:

  1. Atrial fibrillation
  2. Diarrhoea
  3. Confusional state
  4. Drug ineffective
  5. Dyspnoea
  6. Electrocardiogram qt prolonged
  7. Flatulence
  8. Gait disturbance
  9. Left ventricular hypertrophy
  10. Memory impairment

Common Miralax and Clindamycin Phosphate drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Burning sensation
  2. Erythema
  3. Pruritus
  4. Rash
  5. Wisdom teeth removal
  6. Infusion site hypersensitivity

20-29:

  1. Blood urine present
  2. Cardiomyopathy
  3. Decreased appetite
  4. Depression
  5. Drug ineffective
  6. Facial bones fracture
  7. Hallucination
  8. Hyperphagia
  9. Irritability
  10. Osteonecrosis

30-39:

  1. Haematocrit decreased
  2. Haemoglobin decreased
  3. Haemoptysis
  4. Thrombocytopenia
  5. White blood cell count decreased
  6. Arthralgia
  7. Autoimmune thyroiditis
  8. Blood alkaline phosphatase increased
  9. Diarrhoea
  10. Disease progression

40-49:

n/a

50-59:

  1. Diarrhoea
  2. Cellulitis
  3. Injection site pain
  4. Nasopharyngitis
  5. Postoperative abscess

60+:

  1. Atrial fibrillation
  2. Dyspnoea
  3. Atrial flutter
  4. Back pain
  5. Blood glucose increased
  6. Blood iron decreased
  7. Breast mass
  8. Bundle branch block left
  9. Cardiac failure congestive
  10. Confusional state

Common conditions people have *:

  1. Insomnia (sleeplessness): 17 people, 28.33%
  2. Multiple Myeloma (cancer of the plasma cells): 16 people, 26.67%
  3. Pain: 5 people, 8.33%
  4. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 4 people, 6.67%
  5. Lung Cancer - Non-Small Cell (lung cancer): 4 people, 6.67%
  6. Immunodeficiency Common Variable: 4 people, 6.67%
  7. Diarrhea: 3 people, 5.00%
  8. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 3 people, 5.00%
  9. Asthma: 3 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Miralax and Clindamycin phosphate?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Common Miralax and Clindamycin phosphate interactions:

Browse all drug interactions of Miralax and Clindamycin phosphate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Miralax side effects:

Browse all side effects of Miralax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Clindamycin phosphate side effects:

Browse all side effects of Clindamycin phosphate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Miralax interactions:

Browse all interactions between Miralax and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Clindamycin phosphate interactions:

Browse all interactions between Clindamycin phosphate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on polyethylene glycol 3350 and clindamycin phosphate (the active ingredients of Miralax and Clindamycin phosphate, respectively), and Miralax and Clindamycin phosphate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Miralax and Clindamycin phosphate.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: